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Concise Communication

Evaluation of a hybrid antimicrobial restriction process
at a large academic medical center
Jesse D. Smith PharmD candidate 20211, Linh H. Nguyen PharmD candidate 20211,
Tamara Krekel PharmD, BCPS, BCIDP2, Jerrica Waggoner PharmD, BCPS, BCCP3, David J. Ritchie PharmD, BCPS2,4,
Michael J. Durkin MD MPH5, Kevin Hsueh MD5 and Elizabeth A. Neuner PharmD, BCPS, BCIDP2
1

University of Health Sciences and Pharmacy in St. Louis, St. Louis, Missouri, 2Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri, 3Center for
Clinical Excellence, BJC Healthcare, St. Louis, Missouri, 4Pharmacy Practice Department, University of Health Sciences and Pharmacy in St. Louis, St. Louis,
Missouri and 5Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri

Abstract
We conducted a retrospective review of a hybrid antimicrobial restriction process demonstrating adherence to appropriate use criteria in 72%
of provisional-only orders, in 100% of provisional orders followed by ID orders, and in 97% of ID-initiated orders. Therapy interruptions
occurred in 24% of provisional orders followed by ID orders.
(Received 6 May 2021; accepted 3 August 2021)

Preauthorization is a foundational intervention for antimicrobial
stewardship programs. Preauthorization improves initial adherence
to guidelines, decreases Clostridioides difficile infections (CDIs), and
reduces antimicrobial use and costs.1,2 However, a strict preauthorization policy places a heavy workload on the authorizing providers
(particularly after hours), contributes to a perceived loss of prescriber
autonomy, and may contribute to antibiotic administration delays.3,4
In September 2019, the Barnes-Jewish Hospital Antimicrobial
Stewardship Program (BJH-ASP) transitioned from strict preauthorization to a hybrid restriction system to improve patient safety
and reduce the risk of missed orders and delays in therapy. For
select restricted antimicrobials, a provisional order set was created
that allowed up to a 24-hour supply to be utilized without any preauthorization. Additionally, the order set contained an optional
order for an infectious diseases (ID) consultation if therapy beyond
24 hours was desired. Orders for restricted antimicrobials with a
duration longer than 24 hours were limited to ID prescribers only
and a separate order was required for provisional orders to continue beyond 24 hours. All provisional orders are reviewed by
the ASP within 24 hours via real-time notifications when orders
are placed. In this study, we sought to track and describe process
measures related to restricted antimicrobial orders.
Author for correspondence: Elizabeth A. Neuner, Barnes-Jewish Hospital, One
Barnes-Jewish Hospital Plaza, Mailstop 90-52-411, St Louis, Missouri 63110. E-mail:
elizabeth.neuner@bjc.org
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Methods
Inpatients with at least 1 administration of a restricted antimicrobial order from September 19, 2019, to May 19, 2020, at our 1,158bed teaching hospital were included. Restricted antimicrobials
included intravenous acyclovir, ampicillin/sulbactam, ceftazidime/avibactam, ceftolozane/tazobactam, fidaxomicin, and meropenem/vaborbactam. Both acyclovir (September 19, 2019, through
November 18, 2019) and ampicillin/sulbactam (September 19,
2019, through January 13, 2020) were added to the order sets only
during times of shortage. Patients were excluded if the order was
not administered, was a dose adjustment, or was a duplicate.
The primary outcome of the study was the appropriateness of
restricted antimicrobial use, as determined by institutional guidelines (Table 1) for each restriction category (provisional only, provisional followed by ID orders, and ID initiated). Secondary
outcomes included the incidence of therapy interruptions related
to the antimicrobial restriction process. An interruption was
defined delayed administration of the first nonprovisional dose
of a restricted antimicrobial of at least 90 minutes.5
The study was approved by the local institutional review boards.
Results
During the 8-month study period, 177 orders for restricted antimicrobials were placed. Orders were excluded due to no administration (n = 22), dose adjustments (n = 4), and duplicates (n = 2). In
total, 149 orders were included: 43 provisional-only orders, 68 provisional followed by ID orders in 34 patients, and 38 ID-initiated
orders (Table 2). Most provisional-only orders were placed in the
emergency department (28%), compared to the medical intensive
care unit (38%) for the provisional followed by ID orders. The most
common restricted antimicrobials ordered differed among groups:
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Table 1. Appropriate Use Criteria for Restricted Antimicrobials
Antimicrobial
Acyclovir, IV

b

Institution Appropriate Use Criteriaa
• Viral meningitis/encephalitis
• Disseminated herpes simplex virus (HSV)/Varicella
zoster virus (VZV) infection
• HSV/VZV infection in patients unable to take
enteral acyclovir

Ampicillin/
sulbactamb

• Acinetobacter baumannii infections

Ceftazidime/
avibactam

• Definitive treatment of infections caused by
Klebsiella pneumoniae carbapenemase (KPC)–
producing or OXA-48–producing Enterobacterales
when other susceptible therapies are not suitable
based on efficacy and/or safety concerns
• Definitive treatment of infections caused by
multidrug-resistant (MDR) Pseudomonas if the
organism is susceptible to ceftazidime/avibactam
and resistant to cefepime, ceftazidime, ceftolozane/
tazobactam, imipenem, meropenem and
piperacillin/tazobactam, when other susceptible
therapies are not suitable based on efficacy
and/or safety concerns.

Ceftolozane/
tazobactam

Fidaxomicin

Meropenem/
vaborbactam

Table 2. Order Characteristics of Restricted Antimicrobials

• Definitive treatment of infections caused by MDR
Pseudomonas if the organism is susceptible to
ceftolozane/tazobactam and resistant to cefepime,
ceftazidime, imipenem, meropenem and
piperacillin/tazobactam, when other susceptible
therapies are not suitable based on efficacy
and/or safety concerns
• Definitive treatment of recurrent Clostridioides
difficile infection (CDI)
• Definitive treatment of an initial CDI in patients at
high risk for recurrence (age ≥65 years plus severe
disease or receiving concomitant antibiotics)
• Definitive treatment of a KPC-producing
Enterobacterales resistant to ceftazidime/avibactam
but susceptible to meropenem/vaborbactam
• Alternative to ceftazidime/avibactam combination
therapy, meropenem/vaborbactam can be
considered for combined coverage of KPCproducing Enterobacterales AND meropenem/
vaborbactam-susceptible gram-positive organism

a
Indications outside of the appropriate use criteria will be allowed on a case-by-case basis
after discussion with the Barnes-Jewish Hosptial Antimicrobial Stewardship Program.
b
Appropriate use criteria during times of national shortage

Characteristics
Patient location, ICU
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Provisional Orders
Followed By ID
Orders (N = 34),
No. (%)

ID Initiated
(N = 38)
No. (%)

18 (42)

16 (47)

10 (26)

2 (5)

3 (9)

9 (24)

12 (28)

2 (6)

1 (3)

General internal
medicine

2 (5)

4 (12)

6 (16)

General/trauma/
burn surgery

10 (23)

1 (3)

2 (5)

Medical ICU

9 (21)

13 (38)

3 (8)

Neurology/
neurosurgery/
neuro ICU

5 (12)

4 (12)

6 (16)

Oncology/bone
marrow transplant

1 (2)

6 (18)

4 (11)

Othera

2 (5)

1 (3)

7 (18)

Acyclovir, IV

23 (53)

21 (62)

6 (21)

Ampicillin/
sulbactam

13 (30)

1 (3)

5 (18)

3 (9)

2 (7)

Department specialty at
time of initial order
Cardiology/
cardiothoracic
surgery/cardiac
ICU/LVAD
Emergency
medicine

Antimicrobial

Ceftazidime/
avibactam

0

Ceftolozane/
tazobactam

5 (12)

5 (15)

18 (47)

Fidaxomicin

2 (5)

1 (3)

7 (25)

Meropenem/
vaborbactam

0

3 (9)

0

Indication at time of
ordering
Empiric
Definitive

intravenous acyclovir (n = 23, 53%) for provisional-only orders
and (n = 21, 62%) provisional followed by ID orders compared
to ceftolozane/tazobactam (n = 18, 47%) for ID-initiated orders.
Adherence to appropriate use criteria was 72% in provisional-only
orders, 100% for provisional followed by ID orders, and 97% for
ID-initiated orders. ID consultations were ordered for 11 (26%)
of 43 provisional-only orders. Of 43 provisional-only orders, 38
(88%) had documentation of the intent for <24 hours of therapy.
No provisional-only orders were repeated. A review for unintended consequences found no worsening of signs and symptoms
of infection or need for subsequent antimicrobial therapy.
Among the 34 provisional orders followed by ID orders,
8 patients (24%) experienced an interruption in therapy at the
point of transition between the provisional and ID-initiated order:
5 patients experienced an interruption in therapy for intravenous
acyclovir, 1 patient for meropenem/vaborbactam, 1 patient
for ceftazidime/avibactam, and 1 patient for ceftolozane/
tazobactam. The median time for the delayed administration of
an ID-initiated order was 252 minutes (range, 111–650). Review

Provisional
Orders Only
(N = 43),
No. (%)

Prophylaxis

33 (76)

18 (53)

11 (29)

5 (12)

16 (47)

26 (68)

5 (12)

0

1 (3)

31 (72)

34 (100)

Acyclovir, IV

19/23 (83)

21/21 (100)

Ampicillin/
sulbactam

6/13 (46)

1/1 (100)

4/5 (80)

Ceftazidime/
avibactam

0

3/3 (100)

2/2 (100)

Ceftolozane/
tazobactam

4/5 (80)

5/5 (100)

18/18 (100)

Fidaxomicin

2/2 (100)

1/1 (100)

7/7 (100)

Adherent to
appropriate use
criteria

Meropenem/
vaborbactam

0

3/3 (100)

37 (97)

6/6 (100)

0

Note. ID/ASP, infectious diseases/antimicrobial stewardship program; ICU, intensive care
unit; LVAD, left ventricular assist device; IV, intravenous.
a
Other includes 1 pulmonary and 1 otolaryngology provisional-only order; 1 colorectal
surgery for provisional followed by ID order; and 1 colorectal surgery, 1 hepatobiliary surgery/
transplant, 2 otolaryngology, 3 pulmonary ID-initiated–only orders.
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of the interruptions in therapy cases identified documented
reasons for 2 cases: 1 loss of intravenous access and 1 held for
procedure.
Discussion
Our restriction process, which hybridizes a provisional unrestricted system with standard preauthorization, maintained high
adherence (88% overall) to institutional appropriate use criteria.
Use of the restricted antimicrobials (∼14 orders per month)
remained stable during the study period, and we observed no
evidence of teams “gaming” the provisional unrestricted process
to obtain additional doses of restricted agents. These results suggest
that the hybrid process did not lead to unnecessary initiation of
restricted antimicrobials. Our results are comparable to previous
data suggesting that preauthorization improves appropriateness
of restricted antimicrobials. Dassner et al6 evaluated the effect of
a second-sign process for restricted antimicrobials and found
appropriate use was 84.5% by general practitioners and 92.9%
for ID-approved orders. These findings are comparable to the
rates of adherence to appropriate use criteria in our study: 72%
provisional-only orders, 100% provisional followed by ID orders,
and 97% for ID-initiated orders.
Athans et al7 describe an approach to antimicrobial restriction
based on antimicrobial stewardship goals of improving patient
outcomes and safety while reducing resistance and costs. The
BJH-ASP selected agents requiring preauthorization based on
similar principles but also included antimicrobials affected by
shortages. A survey of members of the Emerging Infections
Network in 2016 reported that 70% of ID physicians were affected
by antimicrobial shortages in the previous 2 years and that ASPs
were highly involved in the management.8 Placing durations of
therapy restrictions on antimicrobials experiencing shortages
was a mechanism by which the ASP could monitor usage in real
time. This intervention was effective for acyclovir, with 83%
adherence to use criteria among provisional-only orders and
100% adherence for provisional followed by ID orders. For
ampicillin/sulbactam, only 46% of provisional-only orders were
adherent. This discrepancy was primarily the result of ampicillin/sulbactam use for surgical prophylaxis, not an approved
indication during the shortage.
Interruptions in therapy occurred in the provisional followed
by ID orders; after removal of cases with documented reasons,
interruptions in therapy occurred in 18% of cases. Data suggest
that delays in the first dose of effective antimicrobial therapy
can cause significant patient harm; however, the impact of subsequent delays or interruptions in therapy is much less clear.9
Additionally, the best way to define an interruption in therapy
is uncertain, although they appear to be common. Leisman
et al10 evaluated delays from first- to second-dose antibiotics in
sepsis cases using a definition of delay of ≥25% of the recommended dosing interval, and 33% of patients experienced a major
delay. Even though any delay in therapy is undesirable, in this
hybrid system, delays were not observed with the first dose of antimicrobial and were comparable and no worse than reports in the
literature. Further work is needed to identify reasons for delays and
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how to prevent their occurrence. Our initial investigation did not
identify trends in hours, days of the week, or primary service.
Our study has several limitations. The sample size was small,
and the study was conducted at a single center. We used a retrospective design, and the study lacked a comparator arm. There is
no standard definition for interruption in therapy, and while the
definition in our study was based on Institute for Safe Medication
Practices guidance, it was also conservative.
In conclusion, a hybrid antimicrobial restriction system
demonstrated high adherence to appropriate use criteria, including
short-term criteria introduced as a part of antimicrobial shortage
management processes. Further work is needed to evaluate the
significance of therapy interruptions and to prevent interruptions
in therapy due to preauthorization processes.
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